Vaxcyte, Inc. - COMMON STOCK (PCVX)

Historical Holders from Q2 2020 to Q3 2025

Symbol
PCVX on Nasdaq
CUSIP
92243G108
Type / Class
Equity / COMMON STOCK
Shares outstanding
130M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
141M
Holdings value
$5.09B
% of all portfolios
0.009%
Grand Portfolio weight change
0%
Number of holders
275
Number of buys
130
Number of sells
-145
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Vaxcyte, Inc. - COMMON STOCK (PCVX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 10.1% +7.78% $414M $32.5M 13.1M +8.5% FMR LLC Aug 29, 2025
JANUS HENDERSON GROUP PLC 10.1% -11.8% $472M -$57.2M 13.1M -10.8% JANUS HENDERSON GROUP PLC Sep 30, 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $364M 13M RA Capital Management, L.P. Mar 31, 2025
BlackRock, Inc. 7.6% $276M 9.83M BlackRock, Inc. Mar 31, 2025
T. Rowe Price Investment Management, Inc. 6.4% $300M 8.32M T. Rowe Price Investment Management, Inc. Sep 30, 2025

Institutional Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 141M $5.09B -$217M $36.02 275
2025 Q2 147M $4.79B -$48.2M $32.51 291
2025 Q1 133M $5.02B -$42.9M $37.76 301
2024 Q4 141M $11.5B +$274M $81.86 318
2024 Q3 135M $15.5B +$1.41B $114.27 325
2024 Q2 123M $9.26B +$347M $75.51 266
2024 Q1 118M $8.05B +$1.06B $68.31 235
2023 Q4 304K $19.1M +$1.63M $62.80 3
2023 Q3 101M $5.12B +$57.9M $50.98 198
2023 Q2 99.2M $4.95B +$833M $49.94 194
2023 Q1 84.1M $3.15B +$161M $37.48 183
2022 Q4 81.5M $3.91B +$1.14B $47.95 191
2022 Q3 56.2M $1.35B +$124M $24.00 117
2022 Q2 51.3M $1.12B +$30.5M $21.76 102
2022 Q1 49.8M $1.2B +$125M $24.15 83
2021 Q4 44.7M $1.06B +$31.5M $23.79 81
2021 Q3 43M $1.09B -$1.3M $25.37 75
2021 Q2 43.2M $972M -$13.5M $22.51 72
2021 Q1 36.3M $717M +$25.4M $19.75 71
2020 Q4 42.2M $1.12B +$56.6M $26.57 81
2020 Q3 37.8M $1.86B +$104M $49.38 60
2020 Q2 36M $1.13B +$1.13B $31.61 38